SLC7A11 and colorectal carcinoma: Elesclomol suppressed the malignant progression of CRC by increasing the degradation of copper‐transporting ATPase 1 (ATP7A) and SLC7A11.[112] Moreover, elesclomol inhibited CRC progression by enhancing cellular oxidative stress‐induced ferroptosis.[113] miR‐15a‐3p increased the ROS, intracellular Fe2+ levels, and MDA accumulation by targeting GPX4.